Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sanofi Ord Shs SNYNF

Healthcare
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood... see more

Recent & Breaking News (OTCPK:SNYNF)

SANOFI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Sanofi - SNY

GlobeNewswire December 5, 2014

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Sanofi -- SNY

GlobeNewswire December 5, 2014

EQUITY ALERT: Lawsuit Filed Against Sanofi to Recover Investor Losses - SNY

GlobeNewswire December 5, 2014

Pomerantz Law Firm Announces the Filing of a Class Action Against Sanofi and Certain Officers -- SNY

GlobeNewswire December 4, 2014

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Sanofi

PR Newswire December 4, 2014

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of Sanofi -SNY

PR Newswire December 4, 2014

First MS Patients in the U.S. Receive Genzyme's Lemtrada Following FDA Approval

Business Wire December 3, 2014

Evotec and Sanofi Enter Into Exclusive Negotiations for a Major Multi-Component Strategic Collaboration

GlobeNewswire December 2, 2014

Sanofi Receives FDA Approval of Priftin® (rifapentine) Tablets for the Treatment of Latent Tuberculosis Infection

PR Newswire December 2, 2014

Alberta funds treatment with AUBAGIO® for Relapsing Remitting Multiple Sclerosis

Canada NewsWire December 1, 2014

Australian Diabetes Management Market and Diabetes Diagnostic Devices Market Spurted by $46 Million Between 2005 and 2013

PR Newswire December 1, 2014

European CHMP Adopts Positive Opinion for Genzyme's Cerdelga® (eliglustat) Capsules

Business Wire November 21, 2014

Ontario funds AUBAGIO® for relapsing remitting multiple sclerosis

Canada NewsWire November 20, 2014

Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis

PR Newswire November 20, 2014

Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol

PR Newswire November 19, 2014

Sanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol

PR Newswire November 19, 2014

Genzyme and Isis Present KYNAMRO® Clinical Data at the American Heart Association

Business Wire November 18, 2014

Sanofi Names Chief Scientific Officer Gary Nabel as Sanofi Ebola Response Coordinator

PR Newswire November 18, 2014

Kids bullied because of food allergies. Team Allerject(TM) speaks out.

Canada NewsWire November 17, 2014

Genzyme's Lemtrada Approved by the FDA

Business Wire November 14, 2014